Portal de Periódicos da CAPES

Exercise Intervention for Patients With Transthyretin Amyloid Cardiomyopathy (EXCITE-ATTR-CM) Pilot Study

2023; Elsevier BV; Volume: 40; Issue: 3 Linguagem: Inglês

10.1016/j.cjca.2023.12.014

1916-7075

Fernando Rivera-Theurel, Paul Oh, Paaladinesh Thavendiranathan, Rebecca Laundos, Malak El-Rayes, Natalia Nugaeva, Diego Delgado,

Connective tissue disorders research

Amyloid transthyretin cardiomyopathy (ATTR-CM) is a progressive disease that leads to exercise intolerance and reduced quality of life (QoL). ATTR-CM can be inherited through a pathogenic variation in the transthyretin gene or deposition of the wild type transthyretin protein. Tafamidis is the only disease-modifying therapy approved for ATTR-CM with the potential to reduce the progression of the disease. 1 Badr Eslam R. Öztürk B. Rettl R. et al. Impact of tafamidis and optimal background treatment on physical performance in patients with transthyretin amyloid cardiomyopathy. Circ Hear Fail. 2022; 15: 671-682 Crossref Scopus (16) Google Scholar To date, the effects of an adjunctive exercise strategy, such as cardiac rehabilitation (CR), to improve outcomes in individuals with ATTR-CM has not been studied.